Claims

1. A compound of formula (I);



(I)

wherein:

Y is phenyl, unsubstituted or substituted with one, two or three substituents;

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstitutedC_{1-6} alkyl;

R^2 is $(CH_2)_mR^3$ where m is 0 or 1;

or R^1 and R^2 together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl ring;

R^3 is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group, an unsubstituted or substituted C_{3-8} cycloalkyl group, an unsubstituted or substituted straight or branched C_{1-10} alkyl, an unsubstituted or substituted C_{5-7} cycloalkenyl, R^5 or R^3 is an optionally substituted 5- to 6- membered aromatic heterocyclyl group, or group A:



(A)

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstitutedC_{1-6} alkyl, $COCH_3$, or SO_2Me;

R^5 is



wherein p is 0, 1 or 2, and X is CH_2, O, S, SO or SO_2;

R^6 is halo, an substituted or unsubstituted (C_{1-6})alkyl, substituted or unsubstituted (C_{3-6})cycloalkyl, or a 4- to 7- membered non aromatic heterocyclic group and R^{10} is hydrogen or R^{10} is halo, an substituted or unsubstituted (C_{1-6})alkyl, substituted or unsubstituted (C_{3-6})cycloalkyl, or a 4- to 7- membered non aromatic heterocyclic group and R^6 is hydrogen:

R^7 is OH, C_{1-6}alkoxy, $NR^{8a}R^{8b}$, $NHCOR^9$, $NHSO_2R^9$, $SOqR^9$;

R^{8a} is H or C_{1-6}alkyl;

R^{8b} is H or C_{1-6}alkyl;

R^9 is C_{1-6}alkyl;
R^{12} is hydrogen or C_{1-6}alkyl;
q is 0, 1 or 2;
Ra can be independently selected from hydrogen, fluoro, chloro or trifluoromethyl;
Rb can be independently be selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, haloC_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, COOH or $NHCOOC_{1-6}$alkyl;
or a pharmaceutically acceptable derivative thereof.

2. A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ia):



(Ia)

wherein;
R^3 is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group, an unsubstituted or substituted C_{3-8} cycloalkyl group or a straight or branched C_{1-6}alkyl group;
R^6 is isopropyl, cyclopropyl, trifluoromethyl, *t*-butyl or cyclopentyl;
R^{11} is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;
R^{12} is hydrogen or C_{1-6}alkyl;
d is 0, 1, 2 or 3;
m is 0 or 1;
or a pharmaceutically acceptable derivative thereof.

3. A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ib):



(Ib)

wherein;
R^3 is an optionally substituted 5- to 6- membered aromatic heterocyclyl group, or group A;
R^6 is isopropyl, cyclopropyl, trifluoromethyl, *t*-butyl or cyclopentyl;
R^{11} is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;
R^{12} is hydrogen or C_{1-6}alkyl;
d is 0, 1, 2 or 3;
m is 0 or 1;

or a pharmaceutically acceptable derivative thereof.

4. A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ic):



(Ic)

wherein;

R^1 and R^2 together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl ring;

R^6 is isopropyl, cyclopropyl, trifluoromethyl, *t*-butyl or cyclopentyl;

R^{11} is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;

R^{12} is hydrogen or C_{1-6}alkyl;

d is 0, 1, 2 or 3;

or a pharmaceutically acceptable derivatives thereof.

5. A compound as claimed in Claim 1 selected from Example 1 to 65.

6. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 5 or 2 or a pharmaceutically acceptable derivative thereof and a pharmaceutical carrier or diluent thereof.

7. A pharmaceutical composition as claimed in claim 6 further comprising a second theraputic agent.

8. A pharmaceutical composition as claimed in claim 7 wherein the second therapeutic agent is a PDE4 inhibitor.

9. A method of treating a mammal suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) as claimed in any one of claims 1 to 5 or a pharmaceutically acceptable derivative thereof.

10. A compound of formula (I) as claimed in any one of claims 1 to 5 or a pharmaceutically acceptable derivative thereof for use as a medicament in the treatment of pain.